Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial

被引：0
|
作者：
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Yin, M.
Leppert, D.
Glanzmann, R.
Tinbergen, J.
Hauser, S. L.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Univ Toronto, Toronto, ON, Canada
[5] McGill Univ, Montreal, PQ, Canada
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P462
引用
收藏
页码：S194 / S195
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
    Calabresi, Peter A.
    Radue, Ernst-Wilhelm
    Goodin, Douglas
    Jeffery, Douglas
    Rammohan, Kottil W.
    Reder, Anthony T.
    Vollmer, Timothy
    Agius, Mark A.
    Kappos, Ludwig
    Stites, Tracy
    Li, Bingbing
    Cappiello, Linda
    von Rosenstiel, Philipp
    Lublin, Fred D.
    LANCET NEUROLOGY, 2014, 13 (06): : 545 - 556
  • [22] Daclizumab phase I/II trial in relapsing-remitting multiple sclerosis: MRI and clinical results
    Rose, J.
    Burns, J.
    Bjorklund, J.
    Klein, J.
    Watt, H.
    Carlson, N.
    MULTIPLE SCLEROSIS, 2006, 12 : S105 - S105
  • [23] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
    Sorensen, Per S.
    Lisby, Steen
    Grove, Richard
    Derosier, Frederick
    Shackelford, Steve
    Havrdova, Eva
    Drulovic, Jelena
    Filippi, Massimo
    NEUROLOGY, 2014, 82 (07) : 573 - 581
  • [24] Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial
    Fleming, John
    Hernandez, Gianna
    Hartman, Leslie
    Maksimovic, Jane
    Nace, Sara
    Lawler, Benjamin
    Risa, Todd
    Cook, Thomas
    Agni, Rashmi
    Reichelderfer, Mark
    Luzzio, Christopher
    Rolak, Loren
    Field, Aaron
    Fabry, Zsuzsanna
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (01) : 81 - 91
  • [25] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Paolicelli, Damiano
    Manni, Alessia
    Iaffaldano, Antonio
    Trojano, Maria
    CNS DRUGS, 2020, 34 (01) : 65 - 92
  • [26] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Damiano Paolicelli
    Alessia Manni
    Antonio Iaffaldano
    Maria Trojano
    CNS Drugs, 2020, 34 : 65 - 92
  • [27] Safety of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Bischof, D.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 259 - 259
  • [28] Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis
    Boz, C.
    Ozakbas, S.
    Terzi, M.
    Turkoglu, R.
    Akman, G.
    Efendi, H.
    Akcali, A.
    Tuncer, A.
    Yuceyar, N.
    Turan, O. F.
    Soysal, A.
    Koseoglu, M.
    Balci, B. P.
    Sevim, S.
    Altintas, A.
    Cilingir, V.
    Demirkiran, M.
    Kizilay, F.
    Altunrende, B.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 327 - 328
  • [29] Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 21 - 21
  • [30] Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis
    Hartung, Hans-Peter
    Benedict, Ralph H. B.
    Berger, Thomas
    Bermel, Robert A.
    Brochet, Bruno
    Carroll, William M.
    Freedman, Mark S.
    Holmoy, Trygve
    Karabudak, Rana
    Nos, Carlos
    Patti, Francesco
    Perrin Ross, Amy
    Vanopdenbosch, Ludo
    Vollmer, Timothy
    Wuerfel, Jens
    Clinch, Susanne
    Kadner, Karen
    Kuenzel, Thomas
    Kulyk, Inessa
    Raposo, Catarina
    Thanei, Gian-Andrea
    Killestein, Joep
    NEUROLOGY, 2024, 103 (12)
12345